As pockets fill with cash, Maravai spends $240M to ensure pure mRNA production
A San Diego-based life sciences company is taking over a longtime supplier and California neighbor to boost the purity of its nucleotides and improve the manufacturing process of mRNA, as the boom calls for more demand.
Maravai LifeSciences acquired MyChem for $240 million cash in a move that CEO Carl Hull says will help expand the company’s offering of therapeutics and vaccines.
“The great thing for us is that it allows us to have better control over our supply chain, so that’s a benefit for us and for our customers, but it also allows us to offer more components, more differentiated products to our customers,” he said.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.